ArticleBreast cancer research and treatment2021

Tumor levels of the mediators of ErbB2-driven anoikis resistance correlate with breast cancer relapse in patients receiving trastuzumab-based therapies.

Alexi Surette et al.PubMed ↗Publisher ↗

No numbers read from the abstract.